Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.

Pascal Thomas,G Robinet,R M Ferri-Dessens,H Léna,S Gouva,J M Vernejoux,J P Kleisbauer

Lung cancer (Amsterdam, Netherlands)（2002）

Cited 32|Views2

No score

Abstract

The combination of carboplatin given on day 1 and gemcitabine given on days 1 and 8 every 3 weeks seems to be an acceptable regimen. The DLT consists exclusively of severe thrombocytopenia. Despite the MTD was not reached with carboplatin AUC 6 mg/ml per min and gemcitabine 1500 mg/m(2), the recommended dose for further phase II studies is carboplatin AUC 6 mg/ml per min and gemcitabine 1250 mg/m(2).

Translated text

Key words

COVID-19,Anosmia,IL-6,Prognosis,Mild disease,Cytokine storm,Olfactory dysfunction,Sniffin' Sticks test,Threshold discrimination identification,Computed tomography

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined